Most clinical trials take six to seven years from the first phase of human testing through regulatory approval, though the total can stretch to a decade or more when you include early research and delays. The timeline varies widely depending on the disease being studied, how quickly patients can be enrolled, and whether the treatment qualifies for expedited review. Here’s what each stage looks like and where the biggest delays happen.
The Four Phases of Clinical Trials
Clinical trials move through a series of phases, each with a different purpose and scale. Before any of them begin, a treatment typically spends years in laboratory and animal testing. Once a drug or therapy is ready for human volunteers, the clock starts on Phase 1.
Phase 1 tests a treatment in a small group, usually 20 to 100 people, to evaluate safety and determine appropriate dosing. These trials typically last about two years from the time enrollment opens to the time the study closes out. Participants are monitored closely for side effects, and researchers adjust doses to find the range that’s effective without being harmful.
Phase 2 expands the pool to several hundred participants and focuses on whether the treatment actually works for the targeted condition. These trials generally run two to three years. Researchers begin tracking not just safety but effectiveness, and they refine the dosing further based on how patients respond.
Phase 3 is the largest and longest testing phase, often enrolling thousands of participants across multiple hospitals or clinics. These trials typically take three to four years and compare the new treatment against existing standard treatments or a placebo. The results from Phase 3 are what regulators use to decide whether a treatment should be approved.
Phase 4 happens after a treatment is already on the market. These post-marketing surveillance trials track side effects that emerge over longer periods and in larger, more diverse populations than earlier phases could capture. Phase 4 trials may include thousands of people and can continue for years or even indefinitely, since their purpose is ongoing safety monitoring rather than hitting a specific endpoint.
What Happens After the Trial Ends
Once Phase 3 is complete, the company behind the treatment submits an application to the FDA for review. Under standard review, the FDA’s goal is to make a decision within 10 months. Treatments that address serious conditions or offer a significant improvement over existing options can receive priority review, which shortens that goal to 6 months. Other expedited pathways, like accelerated approval, can compress timelines further for drugs that treat life-threatening diseases with no good alternatives.
The review period isn’t passive waiting. The FDA may request additional data, ask for labeling changes, or require a risk management plan. Some applications sail through; others go back and forth for months beyond the target window.
Why Most Trials Take Longer Than Planned
The single biggest source of delay in clinical trials is patient recruitment. Finding enough eligible participants who are willing to enroll, meet the study criteria, and live close enough to a trial site is harder than most people realize. As of 2023, 85% of clinical trials experienced delays, with nearly a quarter of those facing major setbacks that exceeded 40% of their original timelines. That pattern isn’t new. Reports from 2012 showed that nearly 80% of trials failed to meet their enrollment goals on schedule.
Recruitment challenges compound over time. A Phase 3 trial that needs 3,000 participants across dozens of sites can lose months or even years if enrollment is slow. Strict eligibility criteria, lack of awareness about available trials, geographic barriers, and patients’ reluctance to risk receiving a placebo all contribute. For rare diseases, the pool of eligible patients may be so small that recruitment becomes the defining bottleneck of the entire development process.
Other common delays include manufacturing issues with the treatment itself, regulatory holds triggered by unexpected safety signals, and the logistical complexity of coordinating dozens of research sites across different countries, each with its own regulatory requirements.
How Newer Trial Designs Are Speeding Things Up
Decentralized trials, where some or all study activities happen remotely rather than at a physical clinic, are showing promise in cutting down timelines. A study by the Tufts Center for the Study of Drug Development found that trials using decentralized approaches were more likely to beat their planned timelines for both activating the first site and enrolling the last patient. Remote monitoring, telemedicine check-ins, and at-home sample collection reduce the burden on participants and expand the geographic reach of each trial.
Adaptive trial designs are also gaining traction. Instead of locking in every detail before the trial starts, adaptive designs allow researchers to modify elements like dosing, sample size, or even which patient groups are included based on interim results. This flexibility can shave months off a trial by eliminating ineffective doses early or stopping enrollment in subgroups where the treatment clearly isn’t working.
Combined phase trials, where Phase 1 and Phase 2 run as a single continuous study, are increasingly common in oncology and rare disease research. Rather than completing one phase, analyzing the data, and then designing the next phase from scratch, these seamless designs allow researchers to transition directly from safety testing to efficacy testing within the same study framework.
A Realistic Timeline From Start to Finish
Adding up the phases alone gives a rough estimate of seven to ten years of human testing, but the full picture is longer. Preclinical research, where scientists develop a compound and test it in the lab, often takes three to six years before a treatment ever reaches a human volunteer. Layer on FDA review time, manufacturing scale-up, and the near-inevitable recruitment delays, and the total journey from initial discovery to a drug reaching pharmacy shelves commonly spans 10 to 15 years.
Not every treatment follows that path. During the COVID-19 pandemic, overlapping trial phases, massive government funding, and emergency use authorizations compressed some vaccine timelines to under a year. Those were exceptional circumstances, but they demonstrated that the traditional sequential approach isn’t the only option when urgency and resources align. For most treatments in normal circumstances, though, a decade-plus timeline remains the reality.